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Abstract
Background: Patients infected with Vibrio vulnificus (V. vulnificus) show severe inflammatory responses
characterised by the upregulation of proinflammatory cytokines. Macrophage migration inhibitory factor (MIF), an
upstream proinflammatory regulator, increases the inflammation caused by sepsis. Whether MIF regulates
responses to V. vulnificus infection and the actual mechanism by which V. vulnificus initiates these MIF-modulated
proinflammatory cytokines remain unclear.
Results: MIF increased inflammation during V. vulnificus infection in vivo.I nV. vulnificus-infected mice, MIF was
produced earlier than tumour necrosis factor (TNF)-a and interleukin (IL)-6 and was expressed in a time-dependent
manner. ISO-1 ((S, R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester), a small-molecule
inhibitor of MIF, significantly decreased IL-6, IL-8, and TNF-a production in a time- and dose-dependent manner in
human peripheral blood cells infected with V. vulnificus. The induction of IL-6, IL-8, and TNF-a production by V.
vulnificus infection was mediated via the NF-B- and p38 MAPK-regulated pathways but not via the Akt pathway.
ISO-1-treated human peripheral blood cells showed lower V. vulnificus-induced NF-B activation, IL-6 mRNA
expression, and IB phosphorylation, but they did not show lower p38 MAPK activation.
Conclusions: We conclude that MIF regulates V. vulnificus-induced IL-6 production via NF-B activation and that
p38 MAPK activation in V. vulnificus infection is not MIF dependent.
Background
Vibrio vulnificus (V. vulnificus), a halophilic Gram-negative
bacillus, causes a serious inflammatory process involving
primary septicaemia and soft tissue infections [1]. Patients
with V. vulnificus infections have been reported in north-
ern Europe, the United States, Australia, and Taiwan [2,3].
In the U.S., approximately 50 confirmed cases of V. vulnifi-
cus are reported per year, most of which occur in the Gulf
Coast region. The first case was reported in Taiwan in
1985, and the number of reported infections has increased
because of greater disease activity or improved recognition
by clinicians [3]. Considerable data on the epidemiology of
V. vulnificus has been obtained from Taiwan over the past
two decades, and the involvement of environmental condi-
tions, host factors, and bacterial virulence factors has led
to a clearer understanding of the correlation between
V. vulnificus infections and clinical manifestations. Numer-
ous studies on V. vulnificus have investigated virulence
factors, such as iron-overloading [4] and inflammation-
associated cytokine production [5]. V. vulnificus surface
structures, such as lipopolysaccharide (LPS) and capsular
polysaccharides, increase cytokine production [4,5].
Further, overproduction and dysregulation of the host
cytokine response to V. vulnificus, including tumour nec-
rosis factor (TNF)-a, interleukin (IL)-6, and other inflam-
matory mediators, are critical in V. vulnificus-related
endotoxaemic shock and lead to high mortality [6,7].
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transduction for these proinflammatory cytokines remain
unclear.
Macrophage migration inhibitory factor (MIF), an
important proinflammatory cytokine, is a critical mediator
of innate immunity and is implicated in the pathogenesis
of sepsis [8,9]. Innate immune cells, including activated
T cells, macrophages, and eosinophils, are the primary
sites of MIF production after the host has been exposed to
bacterial endotoxins and exotoxins. The released MIF
modulates the expression of proinflammatory mediators,
leading to early death in patients with sepsis [10-12]. In
mice, the close linkage between MIF expression and
Gram-negative and Gram-positive septic shock strongly
suggests an intrinsic role for MIF in the innate immune
response. Additionally, deleting the MIF gene or immuno-
neutralising MIF attenuates TNF-a production and pro-
tects against endotoxic shock [13,14]. The molecular
mechanism of MIF inhibition in decreasing deleterious
cytokine activity during sepsis is currently under investiga-
tion. MIF-deficient macrophages are hypo-responsive to
stimulation by LPS and Gram-negative bacteria because of
a defect in Toll-like receptor 4 signalling and protein
expression [15]. These findings show that MIF is impor-
tant in innate immunity and provide a rationale for the
development of an anti-MIF strategy to treat patients with
Gram-negative septic shock. The tautomerase active site
of MIF has been proposed [16] as a potential target for
MIF-modulating proinflammatory cytokines and might
be used as a novel anti-inflammatory agent. Isoxazole
acetic acid methyl ester (ISO-1), an inhibitor of MIF d-
dopachrome tautomerase activity, has been shown to inhi-
bit TNF-a secretion from LPS-treated macrophages and
to protect mice from endotoxaemic [17]. The importance
of ISO-1-mediated inhibition of the MIF catalytic site in
the suppression of cytokine proinflammatory activity sug-
gests that the effect of ISO-1 requires endogenous MIF.
MIF binds to the CD74-CD44 complex and induces a
signalling cascade that leads to activation of downstream
signalling molecules, cellular proliferation, and inhibition
of apoptosis by activating the Akt pathway through the
upstream proteins Src and PI3K kinase [18,19]. Nuclear
factor-kappa B (NF-B) and p38 mitogen-activated pro-
tein kinase (MAPK) are also critical intracellular signal
transduction molecules involved in the pathogenesis of
sepsis [20]. NF-B, a ubiquitous transcription factor, is
responsible for the transcription of a diverse range of
genes involved in sepsis and is a critical regulator of
genes that encode TNF-a, IL-6, chemokines, and other
inducible enzymes [21,22]. As with NF-B, p38 MAPK
has been implicated as a critical mediator of the release
of these proinflammatory cytokines during sepsis, and
inhibiting p38 MAPK has an anti-inflammatory effect
both in mice and in human endotoxaemic [20,22]. It
was recently reported [23] that MIF induced the expres-
sion of TNF-related apoptosis, inducing ligand and
monocyte chemoattractant protein 1 in human diabetic
podocytes, and that this MIF-induced expression is also
p38 MAPK dependent. We investigated the effects of
MIF and its molecular actions on proinflammatory cyto-
kine production in V. vulnificus infection.
Methods
Bacterial strains and media
A clinical isolate of encapsulated V. vulnificus,C h i - M e i
Vv05191, was obtained from the Chi-Mei Medical
Center (Tainan, Taiwan) and was prepared as previously
reported [7]. A single colony was chosen and cultured
at 35°C overnight in freshly prepared Mueller-Hinton
broth. The bacterial suspension (400 μl) was then
diluted 1:50 in Mueller-Hinton broth and incubated
under the same conditions for 4 h. Bacteria were col-
lected by centrifugation at 10,000 rpm for 10 min at
24°C. Pellets were resuspended and diluted to an inocu-
lum with a final bacterial concentration of 1 × 10
7 col-
ony-forming units (CFU)/ml (optical density: 0.22-0.25)
before it was injected into mice or co-cultured with
human whole blood or peripheral blood mononuclear
cells (PBMCs). The inoculum concentration was con-
firmed by the subsequent growth of the concurrent
culture on agar plates.
Mice
Inbred BALB/c female mice (age range: 4-5 weeks; mean
weight: 20 g) were purchased from the Animal Center,
National Science Council, Taipei, Taiwan. They were
allowed to acclimatise for 5 to 7 days in the animal
research laboratory of the Chi-Mei Medical Center. Food
a n dw a t e rw e r es u p p l i e da dl i b i t u m .T h ee x p e r i m e n t a l
protocol adhered to the rules of the Animal Protection
Act of Taiwan and was approved by the Laboratory Ani-
mal Care and Use Committee of the Chi-Mei Medical
Center.
Preparing human cells
Buffy coats from healthy blood donors were obtained
both from the Chi-Mei Medical Center and from the
National Cheng Kung University Hospital. PBMCs were
isolated by Ficoll-Hypaque gradient centrifugation
(Pharmacia, Uppsala, Sweden) and prepared at a density
o f2×1 0
6 cells/ml in RPMI. Blood was taken with
informed consent from healthy volunteers in accordance
with a protocol approved by the Human Experiment
and Ethics Committees of both hospitals.
Measuring cytokine concentration
Infected mice were killed 3, 6, 9, and 12 h after they had
been intraperitoneally inoculated with the Vv05191
Chuang et al. BMC Immunology 2010, 11:50
http://www.biomedcentral.com/1471-2172/11/50
Page 2 of 8strain of V. vulnificus. Serum samples obtained from the
left axillary artery were stored at -80°C until they were
assayed. In the infected human-cell model, the bacterial
suspensions were added to whole blood or PBMCs at
multiplicities of infection (MOI, ratio of bacteria to
human PBMCs/whole blood cells) from 1 to 100. At
designated times, plasma or supernatants were collected
for analysis using enzyme-linked immunosorbent assays
(ELISA). To determine the concentrations of cytokines,
ELISA kits including MIF (Chemicon International,
Temecula, CA, CYT264 for mouse and R&D Systems,
Minneapolis, MN, DY289 for human), IL-6 (R&D,
DY406 for mouse and R&D, DY206 for human), IL-8
(R&D, DY208 for human) and TNF-a (R&D, DY410 for
mouse and R&D, DY210 for human), were used accord-
ing to the manufacturer’s instructions.
Inhibitors of MIF, p38 MAPK, NF-B, and Akt
The MIF inhibitor (S, R)-3-(4-hydroxyphenyl)-4,5-dihydro-
5-isoxazole acetic acid methyl ester (ISO-1) was obtained
from Merck KGaA, (Darmstadt, Germany). Neutralising
antibodies against human MIF and control goat IgG were
purchased from R&D Systems. SB203580, pyrrolidine
dithiocarbamate (PDTC), and LY294002 and wortmannin,
selective inhibitors of p38 MAPK, NF-B, and phosphoi-
nositide 3-kinase/Akt, respectively, were purchased from
Tocris Bioscience (Ellisville, MO). All drug treatments
were assessed for cytotoxic effects using cytotoxicity
and viability assays. Doses determined to be harmless
were used.
Western blotting
We harvested the cells and lysed them with a buffer con-
taining 1% Triton X-100, 50 mM Tris [pH 7.5], 10 mM
ethylenediamine tetraacetic acid (EDTA), 0.02% NaN3,
and a protease inhibitor cocktail (Roche Boehringer Man-
nheim Diagnostics, Mannheim, Germany). After they had
been freeze-thawed once, the cell lysates were centrifuged
at 9,000 × g at 4°C for 20 min. The supernatants were
then collected and boiled in sample buffer for 5 min.
After they were separated using SDS-PAGE, the proteins
were transferred to polyvinylidene difluoride (PVDF)
membranes (Millipore, Billerica, MA), blocked at 4°C
overnight in PBS-T (PBS plus 0.05% Tween-20) contain-
ing 5% skim milk, and probed with primary antibodies at
4°C overnight. After they had been washed with PBS-T,
the blots were incubated with a 1:5000 dilution of horse-
radish peroxide (HRP)-conjugated secondary antibody at
4°C for 1 h. The protein bands were visualised using
enhanced chemiluminescence (ECL) (Pierce Biotechnol-
ogy Inc., Rockford, IL), and the relative signal intensity
was quantified using densitometry (LabWorks analysis
software; UVP, LLC, Upland, CA). The extents of IB,
Akt, and p38 MAPK activation were determined using
antibodies against phosphorylation (Cell Signaling Tech-
nology, Beverly, MA).
Electrophoretic mobility shift assays (EMSA)
Nuclear extracts from human PBMCs were prepared
using a method, with minor modifications, described
elsewhere [24]. The cells were washed with 2 ml of
phosphate-buffered saline (PBS) and resuspended in
1 ml of PBS. The cells were then centrifuged at 2,000 ×
g for 2 min, and the supernatant was discarded. The cell
pellet was incubated in 300 μl of buffer A (10 mM
HEPES [pH 7.9], 1.5 mM magnesium chloride, 10 mM
potassium chloride, 0.5 mM phenylmethylsulfonyl fluor-
ide, 0.5 mM dithiothreitol, 2 μg/ml leupeptin, 10 μg/ml
aprotinin, 50 mM sodium fluoride, and 1 mM sodium
orthovanadate) on ice for 10 min and then gently sha-
ken for 10 s. The pellet of the crude nuclei was col-
lected by centrifugation at 12,000 × g for 10 s,
resuspended in 30 μlo fb u f f e rC( 2 0m MH E P E S[ p H
7.9], 25% glycerol, 420 mM sodium chloride, 1.5 mM
magnesium chloride, 0.2 mM EDTA, 0.5 mM phenyl-
methylsulfonyl fluoride, 0.5 mM dithiothreitol, 2 μg/ml
leupeptin, 10 μg/ml aprotinin, 50 mM sodium fluoride,
and 1 mM sodium orthovanadate) using a vortexer for
15 s, and then incubated on ice for 20 min. After the
cells had been centrifuged at 12,000 × g for 2 min, the
supernatant containing the nuclear proteins was col-
lected, quantified (BCA Protein Assay Reagent; Pierce),
and stored in aliquots at -70°C. The EMSA used the fol-
lowing oligonucleotides as probes:
NF- B(f): 5′-CAA ATG TGG GAT TTT CCC ATG
AGT;
NF- B(r): 5′-GAC TCA TGG GAA AAT CCC ACA
TTT G.
The forward and reverse oligonucleotides (30 pmol)
were placed in 23 μl of DNA polymerase buffer (Klenow
1×; Promega), heated at 94°C for 2 min, and then
annealed at room temperature for 30 min. The annealed
double-stranded oligonucleotides were end-labelled
using a fill-in reaction with Klenow. One unit of the
Klenow and 40 μCi of [a-
32P] dCTP (PerkinElmer) were
added to the annealed oligonucleotides, and then the
mixture was incubated at 30°C for 15 min. The labelled
oligonucleotides were purified using G-50 columns
(Sephadex; PerkinElmer Life and Analytical Sciences,
Inc., Boston, MA). The DNA binding reaction was done
at 4°C for 30 min in a mixture containing 3 μgo f
nuclear extract, 10 mM Tris-Cl [pH 7.5], 50 mM
sodium chloride, 0.5 mM dithiothreitol, 0.5 mM EDTA,
1 mM magnesium chloride, 4% glycerol, 0.05 μgo fp o l y
(dI-dC)-poly (dI-dC) (PerkinElmer), and 2 × 10
4 cpm of
32P-labelled double-stranded oligonucleotides. Samples
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bis-acrylamide 29:1 in 0.5× Tris borate-EDTA buffer) at
10 V/cm for 2 h. The gel was dried and analysed using
quantitative autoradiography computer densitometry.
Reverse-transcription polymerase chain reaction (RT-PCR)
The expression of mRNA was assessed using RT-PCR
and quantified by real-time RT-PCR. Total cellular RNA
was extracted from cells using TRIzol reagent (Invitrogen
Corp., Carlsbad, CA) according to the manufacturer’s
instructions. RNA concentrations were quantified using a
spectrophotometer (U-2000; Hitachi Koki Co., Ltd.,
Tokyo, Japan) at 260 nm. cDNA was prepared using
reverse transcription, and PCR was done using a thermal
cycler (GeneAmp PCR system 2400; PerkinElmer). Based
on published sequences and sequences that we designed
with Primer 3 online software http://frodo.wi.mit.edu/
primer3/, we used the following oligonucleotide primers:
b-actin: sense, 5′-TGG AAT CCT GTG GCA TCC
ATG AAA C-3’ and
antisense, 5′-TAA AAC GCA GCT CAG TAA CAG
TCC G-3’;
IL-6: sense, 5′-ATG AAC TCC TTC TCC ACA
AGC GC-3’ and
antisense, 5′-GAA GAG CCC TCA GGC TGG ACT
G-3’.
The PCR products were analysed with 1.5% agarose
gel electrophoresis, stained with ethidium bromide, and
then viewed with ultraviolet (UV) light using a gel cam-
era (UVP) [25]. The levels of IL-6 mRNA were also
quantified using Gene Expression Assays and 2× master
mix on a StepOne Real-Time PCR system (Applied Bio-
systems, California, USA). Cellular RNA was extracted
as described for RT-PCR and the oligonucleotide pri-
mers were as follows:
b-actin: sense, 5′-CTG GAC TTC GAG CAA GAG
ATG-3’ and
antisense, 5′-TGA TGG AGT TGA AGG TAG TTT
CG-3’;
IL-6: sense, 5′-TAC CCC CAG GAG AAG ATT CC-
3’ and
antisense, 5′-CAG TGC CTC TTT GCT GCT TTC-3’.
Statistical analysis
Student’s t test was used to analyse the data (SigmaPlot
8.0 for Windows; Systat Software, Inc., San Jose, CA).
All data are represented by the means ± SD of at least
three individual experiments. P < 0.05 was considered
statistically significant.
Results
MIF was expressed before IL-6 and TNF-a in
V. vulnificus-infected mice
Blood samples from BALB/c mice were collected at 0, 1,
3, 6, 9, and 12 h after they had been infected with
V. vulnificus, and the concentrations of the serum cyto-
kines MIF, IL-6, and TNF-a were determined. Serum MIF
peaked 9 h post-infection and then declined (Figure 1A);
IL-6 and TNF-a (Figures 1B and 1C) continuously
increased. Because our results showed that MIF increased
earlier than IL-6 and TNF-a, we hypothesised that the
early presence of serum MIF acts as an upstream enhan-
cer or modulator of other proinflammatory cytokines,
especially IL-6, during V. vulnificus infection. ISO-1, an
MIF tautomerase inhibitor, was used to observe the
effect of MIF inhibition on cytokine production in
V. vulnificus-infected mice. Inhibition of MIF decreased
V. vulnificus-induced production of IL-6 and TNF-a
(Figure 1D).
Figure 1 The production of serum proinflammatory cytokines
in V. vulnificus-infected mice. BALB/c mice were intraperitoneally
infected with V. vulnificus (Vv05191; 1 × 10
6 CFU) for the indicated
time periods. ELISA was used to determine serum concentrations of
MIF (A), IL-6 (B), and TNF-a (C). (D) With or without ISO-1 (25 mg/
kg) pretreatment for 0.5 h, ELISA was used to determine the serum
concentrations of IL-6 and TNF-a in V. vulnificus-infected mice at 6 h
post-infection. Data are the means ± SD from three individual
experiments. *P < 0.05 vs. non-infected controls or V. vulnificus
infection only.
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We next examined the effect of MIF inhibition on the pro-
duction of the proinflammatory cytokines IL-6, IL-8, and
TNF-a in V. vulnificus-infected human whole blood and
isolated PBMCs. To inhibit MIF, PBMCs were pre-treated
with ISO-1 for 30 min before they were infected with
V. vulnificus. IL-6 (Figure 2A) and IL-8 (Figure 2B) con-
centrations were reduced in a time- and dose-dependent
manner in the plasma of infected human whole blood and
in the supernatant of infected PBMCs. However, the con-
centrations of TNF-a were inhibited unless the cells were
pretreated with high doses ofI S O - 1( F i g u r e2 C ) .M o r e -
over, different MOIs (from 10:1 to 100:1) showed the
same trends of ISO-1 inhibition on IL-6, IL-8, and TNF-a
(data not shown). We also confirmed that V. vulnificus
infection induced MIF production in a time-dependent
manner in infected whole blood and isolated PBMCs
(Figure 2D). TNF-a, IL-6, and IL-8 were downregulated in
V. vulnificus-infected PBMCs treated with neutralising
antibodies to inhibit MIF (Figure 2E). Taken together,
these results show that MIF regulated the production of
IL-6, IL-8, and TNF-a during V. vulnificus infection.
NF-B and p38 MAPK signalling were essential for IL-6,
IL-8, and TNF-a production
We examined whether MIF-induced production of IL-6,
IL-8, and TNF-a was regulated by interfering with intra-
cellular signal transduction. The concentrations of IL-6
(Figure 3A), IL-8 (Figure 3B), and TNF-a (Figure 3C)
were significantly lower in V. vulnificus-infected human
PBMCs treated with pyrrolidine dithiocarbamate
(PDTC, an NF-B inhibitor) and SB203580 (a p38
MAPK inhibitor) but not in PBMCs treated with
LY294002 or wortmannin (Akt inhibitors). These results
indicate that NF-B and p38 MAPK, but not Akt, are
important for modulating IL-6, IL-8, and TNF-a during
V. vulnificus infection.
MIF facilitated NF-B activation
Both NF-B and p38 MAPK are essential mediators of
the response of inflammatory cytokines to either Gram-
negative or Gram-positive bacterial sepsis [20-22,26,27].
We next examined whether MIF modulated NF-B- or
p38 MAPK-dependent signalling transduction during
V. vulnificus-induced proinflammatory activation.
Western blotting showed that the phosphorylation of
IB was lower in ISO-1-treated V. vulnificus-infected
human PBMCs (Figure 4A); however, p38 MAPK phos-
phorylation was not lower (Figure 4B). These results
suggested that MIF is an upstream modulator of
NF-B-dependent signalling for IL-6, IL-8, and TNF-a
production during V. vulnificus infection.
NF-B was essential for the transcriptional activation of
MIF-induced IL-6 expression
Because NF-B is an important transcription factor for
IL-6 expression and binds to its response element on
the IL-6 promoter [20,21,27], we examined whether
increased NF-B binding activity upregulates IL-6 in
V. vulnificus-infected human PBMCs. We used EMSA
with probes containing the putative NF-Bb i n d i n gs i t e
on the IL-6 promoter to measure NF-Bb i n d i n ga c t i v -
ity. After the PBMCs had been infected with V. vulnifi-
cus,N F - B binding was higher in control cells than in
PBMCs treated with ISO-1 (Figure 4C, lanes 2, 3). RT-
PCR and real-time RT-PCR showed that IL-6 mRNA
levels were lower in V. vulnificus-infected PBMCs trea-
ted with ISO-1 than in those not treated with ISO-1
(Figure 4D). Taken together, these results suggest that
MIF is crucial upregulator of IL-6 at the transcription
level in V. vulnificus-infected cells and that this upregu-
lation is the result of NF-B activation.
Figure 2 The effects of ISO-1 on IL-6, IL-8, and TNF-a
production in V. vulnificus-infected whole blood and isolated
PBMCs. Cells pre-treated with different doses of ISO-1 were infected
with V. vulnificus (Vv05191; MOI = 1) for the indicated time periods.
After plasma and supernatants had been collected, ELISA was used
to determine IL-6 (A), IL-8 (B), TNF-a (C), and MIF (D) production. (E)
With or without anti-MIF neutralising antibodies, ELISA was used to
measure the concentrations of TNF-a, IL-6, and IL-8 in V. vulnificus-
infected PBMCs at 4 h post-infection. Control goat IgG and ISO-1
were used as negative and positive controls, respectively. Data are
the means ± SD from three individual experiments. *P < 0.05 vs. V.
vulnificus infection only.
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In this study, we showed that MIF regulated the produc-
tion of TNF-a, IL-6, and IL-8 in V. vulnificus-infected
human PBMCs, which is consistent with the findings of
other studies [8,9]. High serum levels of IL-6, a crucial
immunoregulator in patients with early-phase Gram-
negative sepsis, predict poor outcomes for patients with
sepsis [28,29]. IL-6 increases at early time points in
patients with severe sepsis and septic shock [12,30]. IL-8
also is induced in human intestinal epithelial cells
infected with V. vulnificus, and IL-8 mRNA expression
increases as the result of NF-B activation [31]. In the
present study, we provide evidence that MIF upregulates
IL-6, IL-8, and TNF-a in cells infected with V. vulnifi-
cus. We hypothesise that MIF is an initial proinflamma-
tory mediator during V. vulnificus infection, which is
consistent with previous reports [12,14] on patients with
sepsis and endotoxaemic models.
We showed that V. vulnificus infection significantly
increased IL-6 mRNA expression and NF-Bb i n d i n g
in human PBMCs. We also showed that V. vulnificus
infection increased IL-6 gene expression via NF-B
activation in human PBMCs and that ISO-1, a small
molecule inhibitor of MIF, downregulated the tran-
scription of IL-6 and NF-B activation. While ISO-1
has a different effect on Toll-like receptor 4-induced
inflammatory responses [32], our findings indicate that
IL-6 gene expression is regulated by MIF activation of
Figure 3 The involvement of Akt, NF-B, and p38 MAPK in V.
vulnificus-induced proinflammatory activation. Human PBMCs (2
×1 0
6/ml) were infected with V. vulnificus (Vv05191; MOI = 1) for the
indicated time periods after they had been pre-treated for 30 min
with LY294002 (100 μM), wortmannin (25 nM), PDTC (25 μM), or
SB203580 (25 μM). ELISA was used to determine the concentrations
of IL-6 (A), IL-8 (B), and TNF-a (C). Data are the means ± SD from
three individual experiments. *P < 0.05 vs. V. vulnificus infection only.
Figure 4 The effects of ISO-1 on IB, p38 MAPK activation, NF-
B DNA binding, and IL-6 expression in V. vulnificus-infected
PBMCs. Human PBMCs (2 × 10
6/ml) were infected with V. vulnificus
(Vv05191; MOI = 1) for 1 h and co-treated with ISO-1 (50 μM).
Western blotting was used to measure IB (Ser32) (A) and p38
MAPK (Thr180/Tyr182) (B) phosphorylation. b-actin was the internal
control. Data are representative of three individual experiments. (C)
Effects of ISO-1 on NF-B binding. Nuclear proteins were extracted
from cells after they had been infected with V. vulnificus and co-
treated with or without ISO-1. An EMSA assay was used to analyse
V. vulnificus-infected cells co-treated with ISO-1 for 15 min and to
analyse nuclear proteins (3 μg). Lane 1: Control; Lane 2: V. vulnificus-
infected cells; Lane 3: V. vulnificus-infected cells + ISO-1; Lane 4: ISO-
1 only; (D) Effects of ISO-1 on IL-6 mRNA expression. Human PBMCs
(2 × 10
6/ml) were infected with V. vulnificus (Vv05191; MOI = 1) for
1 h and co-treated with ISO-1 (50 μM). The ratio represents the
quantitative densitometry analysis of bands compared with
untreated controls. b-actin was the internal control. For real-time RT-
PCR analysis, the data is shown as a normalized ratio. Data are
representative of three individual experiments. Data are the means
± SD from three individual experiments. *P < 0.05 vs. V. vulnificus
infection only.
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MIF-regulated proinflammatory cytokines, only high-
dose treatments of ISO-1 inhibited TNF-a production,
which indicated that an MIF-independent signalling
pathway might exist for regulating TNF-a during
V. vulnificus infection.
In the present study, we found that the p38 MAPK
and NF-B pathways were the major signalling pathways
through which cytokine release was induced in human
PBMCs infected with V. vulnificus. Furthermore, a
recent study [26] reported that p38 MAPK was essential
for group B streptococcus-induced MyD88-dependent
induction of TNF-a production but was unnecessary for
NF-B activation [26]. However, based on our findings,
it appears that V. vulnificus-induced IL-6 production is
facilitated by MIF via NF-B activation but not by p38
MAPK. The different responses and their molecular
mechanisms need further investigation.
Inhibiting MIF with ISO-1 downregulated the phos-
phorylation of IB and partially inhibited NF-B binding
activity and the mRNA expression of IL-6, which sug-
gested that MIF is an important upregulator of IL-6
production via NF-B activation. Although the ISO-1-
mediated downregulation of NF-B binding and IL-6
mRNA expression was less significant than the downre-
gulation of IL-6 production, the discrepancy between
the upregulation of transcription and protein production
suggests that these processes are controlled by different
mechanisms. In our preliminary studies, we found a sig-
nificant decrease in protein production after ISO-1
treatment in both the intracellular and extracellular
phases. However, the mechanism that ISO-1 uses to
inhibit intracellular protein production is unknown.
Conclusion
We have shown that MIF significantly upregulated IL-6
production by facilitating NF-B activation in human
PBMCs infected with V. vulnificus. These data may help
in the development of strategies to target MIF with spe-
cific inhibitors or neutralising antibodies when treating
V. vulnificus infection.
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